ReviewCells2026
Regulatory T Cell (Treg): Central Orchestrator of Immune Homeostasis.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulatory T cells (Tregs) play a pivotal role in maintaining immune homeostasis by exerting precise control over immune activation, suppressing excessive responses, and facilitating tissue repair. These specialized CD4+ T cells, characterized by FOXP3 expression, function as key regulators that prevent pathogen-directed immune responses from progressing to deleterious autoimmunity or chronic inflammation. Tregs mediate suppression via secretion of cytokines such as IL-10 and TGF-β, metabolic disruption, and direct modulation of effector immune cells, thereby maintaining equilibrium between protective immunity and peripheral tolerance. Both thymically derived natural Tregs (nTregs) and peripherally induced Tregs (pTregs) exhibit phenotypic plasticity, adapting to diverse inflammatory milieus and tissue microenvironments through an array of suppressive mechanisms that orchestrate immune regulation and facilitate tissue repair. This functional heterogeneity manifests across lymphoid and non-lymphoid tissues, wherein Tregs dynamically adapt to distinct microenvironments to mount tailored responses to infection, tissue injury, and inflammatory insults. Conversely, Tregs may promote disease progression in malignancies and persistent infections by attenuating antitumor and antimicrobial immune effector responses. Treg activity is essential for averting autoimmune pathologies, tempering inflammatory cascades, and fostering tissue regeneration, thereby rendering them indispensable for upholding both systemic and tissue-specific immune homeostasis. Elucidation of Treg immunobiology unveils substantial therapeutic prospects across a diverse array of pathologies; targeted modulation of Treg frequency and functionality offers promise for ameliorating autoimmunity, mitigating transplant rejection, and combating malignancy. This narrative review delineates the multifaceted roles of Tregs in immune homeostasis, elucidates emerging insights into their mechanistic underpinnings, and evaluates prospective applications in next-generation immunotherapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.